BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28006087)

  • 1. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
    Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
    Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
    Sharon E; Kelly RJ; Szabo E
    Head Neck Oncol; 2010 May; 2():12. PubMed ID: 20504363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
    Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
    Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
    Kurzrock R; Bowles DW; Kang H; Meric-Bernstam F; Hainsworth J; Spigel DR; Bose R; Burris H; Sweeney CJ; Beattie MS; Blotner S; Schulze K; Cuchelkar V; Swanton C
    Ann Oncol; 2020 Mar; 31(3):412-421. PubMed ID: 32067683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual gain of HER2 and EGFR gene copy numbers impacts the prognosis of carcinoma ex pleomorphic adenoma.
    Nishijima T; Yamamoto H; Nakano T; Nakashima T; Taguchi K; Masuda M; Motoshita J; Komune S; Oda Y
    Hum Pathol; 2015 Nov; 46(11):1730-43. PubMed ID: 26345124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
    Lee J; Park S; Jung HA; Lee SH; Seo S; Kim SB; Kim JW; Lee KW; Kang EJ; Kim JW; Choi YJ; Shim BY; An HJ; Park LC; Shin SH; Kim JJ; Oh SY; Kim MK; Ahn MJ
    Cancer; 2023 Oct; 129(19):2966-2974. PubMed ID: 37246414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients.
    De Block K; Vander Poorten V; Dormaar T; Nuyts S; Hauben E; Floris G; Deroose CM; Schöffski P; Clement PM
    Acta Clin Belg; 2016 Dec; 71(6):383-388. PubMed ID: 27285571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
    Falchook GS; Lippman SM; Bastida CC; Kurzrock R
    Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study.
    Dori S; Vered M; David R; Buchner A
    J Oral Pathol Med; 2002 Sep; 31(8):463-7. PubMed ID: 12220353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
    Wang K; Russell JS; McDermott JD; Elvin JA; Khaira D; Johnson A; Jennings TA; Ali SM; Murray M; Marshall C; Oldham DS; Washburn D; Wong SJ; Chmielecki J; Yelensky R; Lipson D; Miller VA; Stephens PJ; Serracino HS; Ross JS; Bowles DW
    Clin Cancer Res; 2016 Dec; 22(24):6061-6068. PubMed ID: 27334835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.
    Kaidar-Person O; Billan S; Kuten A
    Med Oncol; 2012 Jun; 29(2):704-6. PubMed ID: 21380780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.
    Gilbert MR; Sharma A; Schmitt NC; Johnson JT; Ferris RL; Duvvuri U; Kim S
    JAMA Otolaryngol Head Neck Surg; 2016 May; 142(5):489-95. PubMed ID: 26939990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab.
    Ghazali N; Parker L; Settle K; Lubek JE
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Sep; 122(3):292-9. PubMed ID: 27289263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in-situ hybridization study.
    Hashimoto K; Yamamoto H; Shiratsuchi H; Nakashima T; Tamiya S; Nishiyama K; Higaki Y; Komune S; Tsuneyoshi M; Oda Y
    Histopathology; 2012 May; 60(6B):E131-42. PubMed ID: 22486195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma.
    Taha T; Billan S
    Anticancer Drugs; 2022 Jan; 33(1):e760-e763. PubMed ID: 34387606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.
    Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A
    Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas.
    Clauditz TS; Reiff M; Gravert L; Gnoss A; Tsourlakis MC; Münscher A; Sauter G; Bokemeyer C; Knecht R; Wilczak W
    Pathology; 2011 Aug; 43(5):459-64. PubMed ID: 21670724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab for the treatment of salivary duct carcinoma.
    Limaye SA; Posner MR; Krane JF; Fonfria M; Lorch JH; Dillon DA; Shreenivas AV; Tishler RB; Haddad RI
    Oncologist; 2013; 18(3):294-300. PubMed ID: 23429737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-erbB-2 oncoprotein expression and amplification in pleomorphic adenoma and carcinoma ex pleomorphic adenoma: relationship to prognosis.
    Müller S; Vigneswaran N; Gansler T; Gramlich T; DeRose PB; Cohen C
    Mod Pathol; 1994 Aug; 7(6):628-32. PubMed ID: 7991521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.